In this review, we discuss the advantages and limitations of current strategies targeting NO/cGMP/PKG signaling in breast cancer, highlighting the therapeutic potential of cGMP hydrolyzing PDE5 inhibitors in a number of preclinical and clinical studies. Here, PDE5A is linked to breast cancer.